Regis Healthcare Ltd. (REG) AI Stock Analysis

• Market Cap: AU$2.26B
• Dividend Yield: 2.11%
• Average Volume (3M): 1.72M
• Price to Earnings (P/E): 46.0
• Beta (1Y): 1.09
• Revenue Growth: 14.61%
• EPS Growth: N/A
• Country: AU
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.08
• Shares Outstanding: 302,361,500
• 10 Day Avg. Volume: 1,078,239
• 30 Day Avg. Volume: 1,722,836
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$8.12
• Price Target Upside: 5.45% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: AU$7.00 ▼(-9.09% Downside)

Regis Healthcare Ltd. has a moderate overall stock score of 51. The financial performance shows some positive trends in revenue and operational efficiency, but high leverage and negative equity pose significant risks. Technical analysis indicates weak momentum, and the valuation suggests the stock might be overvalued. The absence of earnings call data and corporate events limits further insights.

Regis Healthcare Ltd. Business Overview & Revenue Model

Company Description

Regis Healthcare Limited provides residential aged care services in Australia. The company offers home care services, including personal hygiene and care, dressing and undressing, mobility and transportation, rehabilitation, and others; and home help services, such as cleaning, cooking, shopping, transportation, and facilitating social outings. It also provides companionship, and government-funded and private home care services; and owns and operates specialist retirement and independent living villages, which offers laundry, meals, and cleaning, as well as allied health services comprising physiotherapy, podiatry, diversional therapy, and therapeutic activities. In addition, the company provides aged care services, including ageing-in-place, respite care, dementia care, and palliative care services; in-home disability support and veterans' home care services; and therapeutic services to people living in the community, in retirement villages, and low care homes, as well as operates Day Respite centres. As of June 30, 2022, it owned and operated 64 residential aged care homes. The company was formerly known as Fairway Investment Holdings Pty Ltd. and changed its name to Regis Healthcare Limited in 2014. Regis Healthcare Limited was founded in 1994 and is based in Armadale, Australia.

How the Company Makes Money

Regis Healthcare generates revenue primarily through the provision of aged care services, which are funded through a combination of government subsidies, resident fees, and private funding. A significant portion of its income comes from the Australian Government's Aged Care Funding Instrument (ACFI), which allocates funding based on the care needs of residents. Additionally, the company earns revenue from accommodation payments made by residents, which can include both refundable and non-refundable contributions. Regis Healthcare also benefits from strategic partnerships with healthcare providers and organizations that enhance its service offerings and operational efficiencies, contributing to its overall earnings.

Regis Healthcare Ltd. Financial Statement Overview

Summary

Regis Healthcare Ltd. shows signs of revenue recovery and operational efficiency, as evidenced by improved margins. However, the balance sheet reveals high leverage and negative equity, posing financial risks. Cash flow generation is robust, but declining free cash flow growth could be a concern. Overall, while there are positive trends, financial stability remains a challenge.

Income Statement

Regis Healthcare Ltd. has shown a positive revenue growth rate of 4.98% in the latest year, indicating a recovery trend. The gross profit margin has significantly improved to over 100%, suggesting effective cost management. However, the net profit margin remains low at 4.25%, reflecting challenges in converting revenue into profit. The EBIT and EBITDA margins are healthy, indicating operational efficiency.

Balance Sheet

The company has a negative stockholders' equity, resulting in an unfavorable debt-to-equity ratio. This indicates high financial leverage and potential risk. The return on equity is negative, suggesting inefficiencies in generating returns from shareholders' investments. The equity ratio is also concerning, highlighting a reliance on debt financing.

Cash Flow

Operating cash flow is strong relative to net income, indicating good cash generation from operations. However, free cash flow has declined by 9.13%, which could impact future investments. The free cash flow to net income ratio is healthy, suggesting that the company is generating sufficient cash relative to its earnings.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.16B	1.15B	1.01B	771.48M	717.89M	685.87M
Gross Profit	168.77M	141.46M	47.17M	-3.78M	5.18M	67.54M
EBITDA	240.75M	240.44M	191.45M	96.81M	55.86M	82.65M
Net Income	48.95M	48.95M	-21.41M	-28.45M	-38.80M	19.95M
Balance Sheet
Total Assets	2.11B	2.11B	1.81B	1.71B	1.76B	1.75B
Cash, Cash Equivalents and Short-Term Investments	192.47M	192.47M	64.91M	61.32M	4.15M	3.89M
Total Debt	5.11M	5.11M	3.84M	71.07M	113.32M	153.41M
Total Liabilities	2.12B	2.12B	1.84B	1.67B	1.68B	1.61B
Stockholders Equity	-16.72M	-16.72M	-22.89M	38.39M	79.01M	141.97M
Cash Flow
Free Cash Flow	219.64M	219.64M	186.57M	53.73M	67.60M	87.75M
Operating Cash Flow	306.11M	306.11M	252.30M	105.16M	114.79M	105.03M
Investing Cash Flow	-132.74M	-132.74M	-136.59M	6.58M	-48.62M	7.50M
Financing Cash Flow	-45.81M	-45.81M	-112.12M	-43.17M	-62.39M	-119.47M

Regis Healthcare Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:REG, the sentiment is Positive. The current price of 7.7 is above the 20-day moving average (MA) of 6.99, above the 50-day MA of 7.19, and above the 200-day MA of 7.19, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 66.62 is Neutral, neither overbought nor oversold. The STOCH value of 86.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:REG.

Regis Healthcare Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACL	69 Neutral	AU$524.72M	15.63	18.59%	4.90%	6.73%	37.16%
PSQ	63 Neutral	AU$352.32M	178.69	3.28%	―	9.05%	-75.79%
IDX	55 Neutral	AU$977.07M	172.37	0.94%	2.63%	33.54%	―
BOT	53 Neutral	AU$256.19M	-2.78	-90.93%	―	456.50%	-457.14%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
REG	51 Neutral	AU$2.26B	45.97	―	2.11%	14.61%	―
RHC	50 Neutral	$7.10B	1,044.59	0.38%	2.59%	6.82%	-99.27%

Regis Healthcare Ltd. Corporate Events

Regis Healthcare Expands with Acquisition of Two Aged Care Homes

Regis Healthcare Limited has announced the acquisition of two high-quality aged care homes, Ocean Mist Aged Care and Drysdale Grove Aged Care, located on Victoria’s Surf Coast and Bellarine Peninsula. This strategic acquisition, valued at approximately $45 million, will expand Regis’ footprint in Victoria, adding 230 beds to its portfolio. The transaction, expected to complete by December 2025, aligns with Regis’ strategy to broaden its residential aged care services and is anticipated to be earnings per share accretive by FY26. The acquisition not only enhances Regis’ market presence but also offers potential cost synergies and increased earnings through higher occupancy and room pricing.

The most recent analyst rating on (AU:REG) stock is a Buy with a A$8.50 price target. To see the full list of analyst forecasts on Regis Healthcare Ltd. stock, see the AU:REG Stock Forecast page.

Regis Healthcare Adjusts Director’s Incentive Plan

Regis Healthcare Ltd announced a change in the director’s interest notice, specifically regarding Dr. Linda Jane Mellors. The company canceled 4,688 rights granted to Dr. Mellors under the FY2023 Long Term Incentive plan due to unmet performance conditions. This adjustment reflects the company’s adherence to performance-based incentive structures, potentially impacting the director’s future compensation and aligning with shareholder interests.

The most recent analyst rating on (AU:REG) stock is a Buy with a A$8.50 price target. To see the full list of analyst forecasts on Regis Healthcare Ltd. stock, see the AU:REG Stock Forecast page.

Regis Healthcare Ltd. Announces Cessation of Performance Rights

Regis Healthcare Ltd. announced the cessation of 12,235 performance rights due to the conditions for these securities not being met. This development may impact the company’s capital structure and could have implications for stakeholders, reflecting on the company’s operational adjustments and strategic focus.

The most recent analyst rating on (AU:REG) stock is a Buy with a A$8.50 price target. To see the full list of analyst forecasts on Regis Healthcare Ltd. stock, see the AU:REG Stock Forecast page.

Regis Healthcare Ltd. Announces Quotation of New Securities

Regis Healthcare Ltd. announced the quotation of 154,160 ordinary fully paid securities on the ASX, issued under an employee incentive scheme. This move could enhance the company’s market presence and provide liquidity options for its stakeholders, reflecting its strategic efforts to strengthen employee engagement and align interests with company performance.

The most recent analyst rating on (AU:REG) stock is a Buy with a A$8.50 price target. To see the full list of analyst forecasts on Regis Healthcare Ltd. stock, see the AU:REG Stock Forecast page.

Regis Healthcare Announces 2025 Annual General Meeting

Regis Healthcare Ltd. has announced its 2025 Annual General Meeting, scheduled for November 18, 2025, in a hybrid format. Key agenda items include the re-election of directors, adoption of the remuneration report, and approval of performance rights for the CEO. Shareholders are encouraged to participate and submit proxy votes in advance to ensure their voices are heard.

The most recent analyst rating on (AU:REG) stock is a Hold with a A$6.50 price target. To see the full list of analyst forecasts on Regis Healthcare Ltd. stock, see the AU:REG Stock Forecast page.

Regis Healthcare Ltd. Announces Quotation of New Securities

Regis Healthcare Ltd. has announced the quotation of 538,305 ordinary fully paid securities on the Australian Securities Exchange (ASX) as part of an employee incentive scheme. This move is expected to enhance the company’s market presence and potentially improve stakeholder value by aligning employee interests with company growth.

The most recent analyst rating on (AU:REG) stock is a Buy with a A$8.50 price target. To see the full list of analyst forecasts on Regis Healthcare Ltd. stock, see the AU:REG Stock Forecast page.

Regis Healthcare Announces Director’s Interest Change with Strategic Financial Adjustment

Regis Healthcare Ltd announced a change in the director’s interest, specifically regarding Linda Jane Mellors. The change involved the cessation of performance rights under the FY24 STI Plan, where a cash equivalent payment was made instead of allocating ordinary shares. This decision reflects the company’s strategic financial management approach, potentially impacting its financial operations and signaling a focus on liquidity management.

The most recent analyst rating on (AU:REG) stock is a Buy with a A$8.50 price target. To see the full list of analyst forecasts on Regis Healthcare Ltd. stock, see the AU:REG Stock Forecast page.

Regis Healthcare Announces Cessation of Performance Rights

Regis Healthcare Ltd. announced the cessation of 30,840 performance rights, which were canceled by agreement between the entity and the holder as of September 27, 2025. This move may impact the company’s capital structure and could have implications for its financial strategy and stakeholder interests.

The most recent analyst rating on (AU:REG) stock is a Buy with a A$8.50 price target. To see the full list of analyst forecasts on Regis Healthcare Ltd. stock, see the AU:REG Stock Forecast page.

Regis Healthcare Faces Funding Challenges Amid Growth Prospects

Regis Healthcare Limited has announced updates regarding changes in residential aged care funding by the Australian Government, which include a 4.7% increase in the AN-ACC industry starting price. However, Regis anticipates a funding increase of only 2.6% due to reweighting in the National Weighted Activity Unit, leading to reduced funding for key resident classifications. This shortfall, combined with rising staff costs, poses financial challenges. Despite this, the successful acquisition of four Rockpool homes and strong occupancy rates are expected to support cash flows and growth initiatives. Regis projects an FY26 Underlying EBITDA growth of 3% to 7%, reaching $130m to $135m, influenced by these funding changes and operational developments.

The most recent analyst rating on (AU:REG) stock is a Hold with a A$8.50 price target. To see the full list of analyst forecasts on Regis Healthcare Ltd. stock, see the AU:REG Stock Forecast page.

Regis Healthcare Responds to Government’s Aged Care Pricing Changes

Regis Healthcare Limited has acknowledged the Australian Government’s recent announcement regarding increased pricing for the Australian National Aged Care Classification (AN-ACC) and hotelling supplement. These changes are aimed at funding wage increases for direct care workers and nurses as per the Fair Work Commission’s recommendations. Regis is currently assessing the financial implications of these changes and will continue to update the market in line with its disclosure obligations.

The most recent analyst rating on (AU:REG) stock is a Hold with a A$7.50 price target. To see the full list of analyst forecasts on Regis Healthcare Ltd. stock, see the AU:REG Stock Forecast page.

Regis Healthcare Director Increases Shareholding

Regis Healthcare Ltd has announced a change in the director’s interest notice, specifically regarding Sally Margaret Freeman. The director acquired 4,805 ordinary shares on the market, increasing her total holdings to 87,267 shares. This acquisition reflects a strategic move in the company’s governance, potentially impacting its market perception and stakeholder confidence.

The most recent analyst rating on (AU:REG) stock is a Buy with a A$9.00 price target. To see the full list of analyst forecasts on Regis Healthcare Ltd. stock, see the AU:REG Stock Forecast page.

Regis Healthcare Director Increases Shareholding

Regis Healthcare Ltd announced a change in the director’s interest, with Graham Kennedy Hodges acquiring 22,000 ordinary shares, increasing his total holdings to 132,000 shares. This acquisition, valued at $170,588.70, was conducted through an on-market trade, reflecting a potential vote of confidence in the company’s future prospects by its director.

The most recent analyst rating on (AU:REG) stock is a Buy with a A$9.00 price target. To see the full list of analyst forecasts on Regis Healthcare Ltd. stock, see the AU:REG Stock Forecast page.

Regis Healthcare Director Increases Stake in Company

Regis Healthcare Ltd announced a change in the director’s interest notice, with Jodie Lee Leonard acquiring 12,500 ordinary shares, increasing her indirect interest to 23,705 shares. This acquisition reflects a strategic move by the director, potentially indicating confidence in the company’s future prospects, which could have implications for stakeholders and market perception.

The most recent analyst rating on (AU:REG) stock is a Buy with a A$9.00 price target. To see the full list of analyst forecasts on Regis Healthcare Ltd. stock, see the AU:REG Stock Forecast page.

Regis Healthcare Sets Date for Annual General Meeting

Regis Healthcare Limited has announced that its Annual General Meeting will be held on November 18, 2025. The company has set September 15, 2025, as the deadline for director nominations. This meeting is a significant event for stakeholders as it provides insights into the company’s future direction and governance.

The most recent analyst rating on (AU:REG) stock is a Buy with a A$9.00 price target. To see the full list of analyst forecasts on Regis Healthcare Ltd. stock, see the AU:REG Stock Forecast page.

Regis Healthcare Ltd. Releases 2025 Corporate Governance Statement

Regis Healthcare Ltd. has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. This statement outlines the company’s adherence to the ASX Corporate Governance Council’s recommendations, highlighting their commitment to transparency and accountability in their management practices. The announcement underscores the company’s dedication to maintaining robust governance structures, which is crucial for its stakeholders and enhances its industry positioning.

The most recent analyst rating on (AU:REG) stock is a Hold with a A$8.00 price target. To see the full list of analyst forecasts on Regis Healthcare Ltd. stock, see the AU:REG Stock Forecast page.

Regis Healthcare Reports Strong Financial Recovery in 2025

Regis Healthcare Ltd. reported a significant improvement in its financial performance for the year ended June 30, 2025, with a 14.5% increase in revenue and a 328.6% rise in statutory net profit after tax. The company’s earnings per share also saw a substantial increase, reflecting a strong recovery from the previous year’s losses. This positive financial outcome is likely to enhance Regis Healthcare’s market positioning and provide confidence to its stakeholders.

The most recent analyst rating on (AU:REG) stock is a Hold with a A$8.00 price target. To see the full list of analyst forecasts on Regis Healthcare Ltd. stock, see the AU:REG Stock Forecast page.